<DOC>
	<DOCNO>NCT02579239</DOCNO>
	<brief_summary>The purpose study assess safety biological activity ATYR1940 patient Limb Girdle ( LGMD2B ) Facioscapulohumeral Muscular Dystrophy ( FSHD ) .</brief_summary>
	<brief_title>The Safety Biological Activity ATYR1940 Patients With Limb Girdle Facioscapulohumeral Muscular Dystrophies</brief_title>
	<detailed_description>ATYR1940-C-004 Phase1b/2 open-label intrapatient study dose escalation study aim evaluate safety , tolerability , immunogenicity , biological activity intravenous ATYR1940 , administer weekly 8 week , twice weekly 4 week adult patient LGMD2B FSHD . Approximately 8 LGMD2B 8 FHSD patient enrol .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Facioscapulohumeral</mesh_term>
	<mesh_term>Muscular Dystrophies , Limb-Girdle</mesh_term>
	<criteria>Provided informed consent Investigator 's opinion , patient willing able complete study procedure comply study visit schedule . Patients LGMD2B : Established , genetically confirm diagnosis LGMD2B . Either presence STIRpositive muscle lower extremity skeletal muscle MRI , , STIRpositive muscle , meet muscle biomarker criterion . Patients FSHD : Established , genetically confirm diagnosis FSHD . The presence STIRpositive muscle low extremity skeletal muscle MRI . Currently receive treatment immunomodulatory agent , include target biological therapy within 3 month baseline ; corticosteroid within 3 month baseline ; highdose nonsteroidal antiinflammatory agent within 2 week baseline . Currently receive curcumin albuterol ; use product putatively enhance muscle growth chronic basis within 4 week baseline ; statin treatment initiation significant adjustment statin regimen within 3 month baseline ( stable , chronic statin use permissible ) . Use investigational product device within 30 day baseline . Evidence alternative diagnosis LGMD2B FSHD coexist myopathy dystrophy , base prior muscle biopsy available investigation . History severe restrictive obstructive lung disease evidence interstitial lung disease screen chest radiograph . History antisynthetase syndrome , prior Jo1 Abpositivity , positive equivocally positive Jo1 Ab test result screening . Chronic infection , hepatitis B , hepatitis C , human immunodeficiency virus history tuberculosis . Vaccination within 8 week baseline vaccination plan study participation . Symptomatic cardiomyopathy severe cardiac arrhythmia may Investigator 's opinion , limit patient 's ability complete study protocol . Muscle biopsy within 30 day baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>LGMD2B</keyword>
	<keyword>FSHD</keyword>
</DOC>